home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

5.560 -0.210 (-3.64%)

Streaming Delayed Price Updated: 12:50 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Evolus to Report Second Quarter 2022 Results and Provide Business Update

July 19, 2022

From Evolus

Via Business Wire

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

July 19, 2022

From Evolus

Via Business Wire

Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

July 12, 2022

From Evolus

Via Business Wire

Needham Is Bullish On This Botox Equivalent Aesthetics Company ↗

June 24, 2022

Via Benzinga

Recap: Evolus Q4 Earnings ↗

March 03, 2022

Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed...

Via Benzinga

A Preview Of Evolus's Earnings ↗

March 02, 2022

Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Evolus's Return On Capital Employed Overview ↗

June 10, 2022

According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million.

Via Benzinga

Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed

June 02, 2022

From Evolus

Via Business Wire

Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States

May 18, 2022

From Evolus

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022 ↗

May 13, 2022

Upgrades

Via Benzinga

Evolus to Participate in the H.C. Wainwright Global Investment Conference

May 11, 2022

From Evolus

Via Business Wire

Evolus: Q1 Earnings Insights ↗

May 10, 2022

Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,...

Via Benzinga

Evolus Reports First Quarter 2022 Results and Provides Business Update

May 10, 2022

From Evolus

Via Business Wire

Evolus to Report First Quarter 2022 Results and Provide Business Update

April 26, 2022

From Evolus

Via Business Wire

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

March 31, 2022

From Evolus

Via Business Wire

EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 29, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Evolus's Return On Capital Employed Insights ↗

March 09, 2022

According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million...

Via Benzinga

Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook ↗

March 04, 2022

Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update

February 17, 2022

From Evolus

Via Business Wire

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®

February 08, 2022

From Evolus

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 07, 2022

Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of...

Via Benzinga

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

February 02, 2022

From Evolus, Inc.

Via Business Wire

41 Biggest Movers From Yesterday ↗

January 27, 2022

Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 26, 2022

Gainers Rani Therapeutics Hldgs (NASDAQ:RANI

Via Benzinga

Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance ↗

January 26, 2022

Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher...

Via Benzinga

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance

January 26, 2022

From Evolus, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 ↗

January 20, 2022

Upgrades For W.P. Carey Inc (NYSE:WPC), B...

Via Benzinga

Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart

January 05, 2022

From Evolus

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com